DIG
UNCY icon

Dauntless Investment Group’s Unicycive Therapeutics UNCY Stock Holding History

Dauntless Investment Group’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$968K Buy
147,087
+57,672
+64% +$378K 0.64% 21
2025
Q4 		$516K Buy
+89,415
New +$477K 0.41% 34

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dauntless Investment Group's UNCY Position: Q1 2026 in Review

Dauntless Investment Group increased its Unicycive Therapeutics (UNCY) stake by 64% in Q1 2026, buying an estimated $378K and bringing the position to 147,087 shares worth $968K. The position accounts for 0.64% of the portfolio, ranked #21.

Dauntless Investment Group first reported a position in UNCY in Q4 2025 and has held it in 2 quarters since. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Dauntless Investment Group held 147,087 shares of Unicycive Therapeutics worth $968K as of Q1 2026.
  • Dauntless Investment Group bought 57,672 Unicycive Therapeutics shares in Q1 2026, an estimated $378K.
  • Unicycive Therapeutics made up 0.64% of Dauntless Investment Group's portfolio in Q1 2026, its #21 holding.
  • Dauntless Investment Group first reported a position in Unicycive Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Dauntless Investment Group's 13F filing for Q1 2026, filed 14 May 2026.